Preeclampsia Risk Assessment Using Angiogenic Biomarkers in Hospitalized Patients: Evidence, Implementation, and Clinical Cases

Webinar Summary:

Join Dr. Sarosh Rana, MD, MPH as she discusses the scientific evidence and clinical impact of implementing the angiogenic biomarkers into the management of preeclampsia with severe features.

In this webinar, several key studies investigating the clinical utility of the angiogenic biomarkers will be reviewed, including the PRAECIS study (one of the largest studies conducted in the U.S.) which demonstrated that a sFlt-1/PlGF ratio cut-off of 40 was able to adequately stratify the risk of pregnant patients hospitalized with hypertension (between 23 and 35 weeks gestation) for progression to severe preeclampsia within two weeks. In addition, these markers also had a strong association with the duration of the remainder of the pregnancy and adverse maternal and fetal outcomes.
 

The FDA has since approved the use of sFlt-1/PlGF to predict the risk of severe preeclampsia. Dr. Rana will also discuss several case studies post-FDA approval which demonstrate the clinical utility of the biomarkers in a real-world setting.
 

Please join Dr. Rana to discuss the angiogenic biomarkers and the clinical impact of sFlt-1/PlGF in obstetrical practice in the U.S.